Literature DB >> 23025133

Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces.

George Loeffler1, Donald Hurst, Ashley Penn, Kathryn Yung.   

Abstract

Designer drugs are synthetic compounds that contain modified molecular structures of illegal or controlled substances. They are produced clandestinely with the intent to elicit effects similar to controlled substances while circumventing existing drug laws. Two classes of designer drugs that have risen to recent prominence are "spice," synthetic cannabinoid receptor agonists that mimic the effect of tetrahydrocannabinol, the active ingredient in cannabis, and "bath salts," synthetic cathinones, stimulants structurally related to amphetamines that have effects similar to cocaine and methamphetamine. Although these substances have only gained prominence recently, service members of the U.S. armed forces have not been immune to spice and bath salt abuse. These substances are often perceived as safe and are available via the Internet, in head shops and from dealers. Spice and bath salt abuse is increasingly associated with serious medical and psychiatric problems. Military health care providers must be familiar with these important new classes of drugs. This article discusses the background, current civilian and military legal status, clinical effects, pharmacology, and clinical management of synthetic cannabinoid receptor agonists and synthetic cathinones.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23025133     DOI: 10.7205/milmed-d-12-00180

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  11 in total

Review 1.  Spicing things up: synthetic cannabinoids.

Authors:  Max Spaderna; Peter H Addy; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

Review 2.  Psychoactive Bath Salts and Neurotoxicity Risk.

Authors:  Beril Altun; İsmet Çok
Journal:  Turk J Pharm Sci       Date:  2020-04-24

3.  Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study.

Authors:  Andrew A Monte; Diane P Calello; Roy R Gerona; Eike Hamad; Sharan L Campleman; Jeffery Brent; Paul Wax; Robert G Carlson
Journal:  J Med Toxicol       Date:  2017-04-10

Review 4.  Marijuana Use and Organ Transplantation: a Review and Implications for Clinical Practice.

Authors:  Harinder Singh Rai; Gerald Scott Winder
Journal:  Curr Psychiatry Rep       Date:  2017-10-27       Impact factor: 5.285

5.  Evaluation of Acetylfentanyl Following Suspected Heroin Overdose When Complicated by the Presence of Toxic Fentanyl and Alprazolam Concentrations.

Authors:  Michael Fagiola; Timothy Hahn; Joseph Avella
Journal:  Acad Forensic Pathol       Date:  2020-01-31

6.  Designer drugs 2015: assessment and management.

Authors:  Michael F Weaver; John A Hopper; Erik W Gunderson
Journal:  Addict Sci Clin Pract       Date:  2015-03-25

Review 7.  Neurotoxicity Induced by Mephedrone: An up-to-date Review.

Authors:  Flaminia Pantano; Roberta Tittarelli; Giulio Mannocchi; Roberta Pacifici; Alessandro di Luca; Francesco Paolo Busardò; Enrico Marinelli
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

8.  Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.

Authors:  Szilvia Kassai; Judit Nóra Pintér; József Rácz; Brigitta Böröndi; Tamás Tóth-Karikó; Kitti Kerekes; V Anna Gyarmathy
Journal:  Harm Reduct J       Date:  2017-02-10

Review 9.  The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids-A Systematic Review.

Authors:  Koby Cohen; Aviv Weinstein
Journal:  Brain Sci       Date:  2018-02-27

Review 10.  Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.

Authors:  Koby Cohen; Aviv M Weinstein
Journal:  Front Public Health       Date:  2018-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.